/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

C

Carla J. de Boer

Janssen (Netherlands)(NL)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

45

Papers

2.9K

Citations

18

h-index

20

i10-index

Carla J. de Boer is an academic researcher from Janssen (Netherlands). The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Multiple Myeloma Research and Treatments & Prostate Cancer Treatment and Research. The author has an h-index of 18, co-authored 39 publications.

Research Topics

Lymphoma Diagnosis and Treatment Multiple Myeloma Research and Treatments Prostate Cancer Treatment and Research Chronic Lymphocytic Leukemia Research Quinazolinone synthesis and applications

Papers by this author

works

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

2023 · New England Journal of Medicine · 469 citations

https://doi.org/10.1056/nejmoa2312054

Pieter Sonneveld Meletios Α. Dimopoulos Mario Boccadoro Hang Quach

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

2011 · British Journal of Cancer · 115 citations

https://doi.org/10.1038/bjc.2011.183

Steven O’Day Anna C. Pavlick Carmen Loquai David H. Lawson

MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations

https://doi.org/10.1016/s2152-2650(24)01669-0

Pieter Sonneveld Philippe Moreau Meletios Α. Dimopoulos Hang Quach

MM-491 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations

https://doi.org/10.1016/s2152-2650(24)01688-4

Philippe Moreau Cyrille Hulin Aurore Perrot Bertrand Arnulf

Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations

https://doi.org/10.1016/s2152-2650(24)00975-3

Philippe Moreau Cyrille Hulin Aurore Perrot Bertrand Arnulf

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations

https://doi.org/10.1016/s2152-2650(24)00956-x

Pieter Sonneveld Philippe Moreau Meletios Α. Dimopoulos Hang Quach

Research topics

topics

Lymphoma Diagnosis and Treatment

Multiple Myeloma Research and Treatments

Prostate Cancer Treatment and Research

Chronic Lymphocytic Leukemia Research

Quinazolinone synthesis and applications

Chat about Author

Papers

Chat

Click to start Chat